Pharmacokinetic considerations and recommendations in palliative care, with focus on morphine, midazolam and haloperidol

Linda Franken, Brenda de Winter, HJ van Esch, Lia Zuylen, FPM (Frans) Baar, Dick Tibboel, RAA Mathot, Teun Gelder, Birgit Koch

Research output: Contribution to journalArticleAcademicpeer-review

39 Citations (Scopus)
20 Downloads (Pure)


Introduction: A variety of medications are used for symptom control in palliative care, such as morphine, midazolam and haloperidol. The pharmacokinetics of these drugs may be altered in these patients as a result of physiological changes that occur at the end stage of life. Areas covered: This review gives an overview of how the pharmacokinetics in terminally ill patients may differ from the average population and discusses the effect of terminal illness on each of the four pharmacokinetic processes absorption, distribution, metabolism, and elimination. Specific considerations are also given for three commonly prescribed drugs in palliative care: morphine, midazolam and haloperidol). Expert opinion: The pharmacokinetics of drugs in terminally ill patients can be complex and limited evidence exists on guided drug use in this population. To improve the quality of life of these patients, more knowledge and more pharmacokinetic/pharmacodynamics studies in terminally ill patients are needed to develop individualised dosing guidelines. Until then knowledge of pharmacokinetics and the physiological changes that occur in the final days of life can provide a base for dosing adjustments that will improve the quality of life of terminally ill patients. As the interaction of drugs with the physiology of dying is complex, pharmacological treatment is probably best assessed in a multi-disciplinary setting and the advice of a pharmacist, or clinical pharmacologist, is highly recommended.
Original languageUndefined/Unknown
Pages (from-to)669-680
Number of pages12
JournalExpert Opinion on Drug Metabolism & Toxicology
Issue number6
Publication statusPublished - 2016

Research programs

  • EMC MGC-02-53-01-A
  • EMC OR-01-34-01
  • EMC OR-01-86-13

Cite this